Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma. Pembrolizumab was approved for use in combination with platinum and fluorouracil for all patients and as a single agent for patients whose tumors express PD‑L1 (combined positive score, ≥1) as determined by an FDA‑approved test.
October 2019—ARUP Laboratories and Techcyte, a developer of artificial intelligence–based image analysis solutions for the diagnostics industry, have developed an AI-augmented ova and parasite detection tool.
October 2019—Myriad Genetics announced publication of results from a study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer (Canter DJ, et al. Prostate Cancer Prostatic Dis. Epub ahead of print June 27, 2019). The pooled analysis included 1,062 men with localized prostate cancer who were definitively treated with surgery (n = 800) or radiation (n = 262). The primary objective was to evaluate the ability of the Prolaris test (CCP score)
October 2019—The U.S. Federal Bureau of Investigation has approved Thermo Fisher Scientific’s Applied Biosystems Precision ID System mtDNA analysis solution for use by forensic laboratories to generate mitochondrial DNA profiles for submission to the U.S. National DNA Index System CODIS database.
October 2019—Helmer Scientific launched its upright laboratory, pharmacy, and blood bank GX Solutions refrigerators, with models ranging from 13 to 56 cubic feet. GX Solutions are designed to keep temperatures within ±1°C throughout the unit, recover quickly from temperature changes after prolonged door openings, and maintain temperature stability.
October 2019—Biodesix (Boulder, Colo.) announced that it will acquire Oncimmune’s U.S. operations, which include a CLIA lab in De Soto, Kan., and the company’s incidental pulmonary nodule malignancy test, Early-CDT Lung.
October 2019—Randox Laboratories announced that the NGSP has awarded it with a manufacturer certification for direct HbA1c testing on three of the company’s clinical chemistry analyzers, the RX Modena, RX Imola, and RX Daytona+.
October 2019—Menarini Silicon Biosystems launched its VRNxT, a sample preparation instrument that automates volume reduction steps in rare cell analysis workflows.
October 2019—Bio-Rad Laboratories received FDA 510(k) clearance for its IH-500, an automated random access system for blood typing and screening, designed for small to medium-size laboratories. The system can process Bio-Rad’s range of IH gel cards for ABO blood grouping, reverse testing, phenotyping, Rh subgroups, antibody screening, antibody identification, single antigen testing, direct AHG testing, and crossmatching. In a separate release, the company announced FDA clearance for its BioPlex 2200 Lyme Total Assay, a multiplex test method to aid in
October 2019—The FDA approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first noninsulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
